{
    "nctId": "NCT00082641",
    "briefTitle": "Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer",
    "officialTitle": "1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Number of Participants Who Experienced Toxicity to the Vaccine",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed invasive breast cancer meeting the following criteria:\n\n  * Clinically locally advanced disease (stage III) with a primary tumor at least 4 cm by mammogram, ultrasound, or palpation AND/OR palpable axillary nodes larger than 1 cm\n  * Planned neoadjuvant chemotherapy\n* p53-overexpressing tumor by immunohistochemistry\n* Delayed-type hypersensitivity to at least 1 of 3 standard antigens\n* Female\n* ECOG 0-1\n* WBC \\> 4,000/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n* Bilirubin \\< 2 times upper limit of normal (ULN)\n* Hepatitis B surface antigen negative\n* Hepatitis C antibody negative\n* Creatinine \\< 2 times ULNHIV negative\n* Fertile patients must use effective contraception during and for at least 6 months after study participation\n\nExclusion Criteria:\n\n* No prior or concurrent autoimmune disorder\n* Not pregnant or nursing/negative pregnancy test\n* No other concurrent illness that would preclude study participation\n* No prior chemotherapy\n* No concurrent participation in another therapeutic clinical trial",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}